|
1
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Simonnet H, Alazard N, Pfeiffer K, Gallou
C, Béroud C, Demont J, Bouvier R, Schägger H and Godinot C: Low
mitochondrial respiratory chain content correlates with tumor
aggressiveness in renal cell carcinoma. Carcinogenesis. 23:759–768.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang K, He B, Lai L, Chen Q, Liu Y, Guo Q
and Wang Q: Cyclosporine A inhibits breast cancer cell growth by
downregulating the expression of pyruvate kinase subtype M2. Int J
Mol Med. 30:302–308. 2012.PubMed/NCBI
|
|
4
|
Furtado CM, Marcondes MC, Sola-Penna M, de
Souza ML and Zancan P: Clotrimazole preferentially inhibits human
breast cancer cell proliferation, viability and glycolysis. PLoS
One. 7:e304622012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kosugi M, Ahmad R, Alam M, Uchida Y and
Kufe D: MUC1-C oncoprotein regulates glycolysis and pyruvate kinase
M2 activity in cancer cells. PLoS One. 6:e282342011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jurica MS, Mesecar A, Heath PJ, Shi W,
Nowak T and Stoddard BL: The allosteric regulation of pyruvate
kinase by fructose-1,6-bisphosphate. Structure. 6:195–210. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Christofk HR, Van der Heiden MG, Harris
MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL and
Cantley LC: The M2 splice isoform of pyruvate kinase is important
for cancer metabolism and tumour growth. Nature. 452:230–233. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Christofk HR, Van der Heiden MG, Wu N,
Asara JM and Cantley LC: Pyruvate kinase M2 is a
phosphotyrosine-binding protein. Nature. 452:181–186. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang W, Xia Y, Ji H, Zheng Y, Liang J,
Huang W, Gao X, Aldape K and Lu Z: Nuclear PKM2 regulates β-catenin
transactivation upon EGFR activation. Nature. 480:118–122. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anastasiou D, Poulogiannis G, Asara JM,
Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW,
Auld DS, et al: Inhibition of pyruvate kinase M2 by reactive oxygen
species contributes to cellular antioxidant responses. Science.
334:1278–1283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goldberg MS and Sharp PA: Pyruvate kinase
M2-specific siRNA induces apoptosis and tumor regression. J Exp
Med. 209:217–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang LY, Liu YP, Chen LG, Chen YL, Tan L,
Liu JJ, Jazag A, Ren JL and Guleng B: Pyruvate kinase M2 plays a
dual role on regulation of the EGF/EGFR signaling via
E-cadherin-dependent manner in gastric cancer cells. PLoS One.
8:e675422013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW,
Choi SH and Cho JY: Overexpression of the M2 isoform of pyruvate
kinase is an adverse prognostic factor for signet ring cell gastric
cancer. World J Gastroenterol. 18:4037–4043. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kwon OH, Kang TW, Kim JH, Kim M, Noh SM,
Song KS, Yoo HS, Kim WH, Xie Z, Pocalyko D, et al: Pyruvate kinase
M2 promotes the growth of gastric cancer cells via regulation of
Bcl-xL expression at transcriptional level. Biochem Biophys Res
Commun. 423:38–44. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blume H, Donath F, Warnke A and Schug BS:
Pharmacokinetic drug interaction profiles of proton pump
inhibitors. Drug Saf. 29:769–784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shen Y, Wu Y, Chen M, Shen W, Huang S,
Zhang L and Zou X: Effects of pantoprazole as a HIF-1α inhibitor on
human gastric adenocarcinoma sgc-7901 cells. Neoplasma. 59:142–149.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tao T, Li G, Dong Q, Liu D, Liu C, Han D,
Huang Y, Chen S, Xu B and Chen M: Loss of SNAIL inhibits cellular
growth and metabolism through the miR-128-mediated
RPS6KB1/HIF-1α/PKM2 signaling pathway in prostate cancer cells.
Tumour Biol. 35:8543–8550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yeo M, Kim DK, Kim YB, Oh TY, Lee JE, Cho
SW, Kim HC and Hahm KB: Selective induction of apoptosis with
proton pump inhibitor in gastric cancer cells. Clin Cancer Res.
10:8687–8696. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Czernin J and Phelps ME: Positron emission
tomography scanning: Current and future applications. Annu Rev Med.
53:89–112. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gambhir SS: Molecular imaging of cancer
with positron emission tomography. Nat Rev Cancer. 2:683–693. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shi HS, Li D, Zhang J, Wang YS, Yang L,
Zhang HL, Wang XH, Mu B, Wang W, Ma Y, et al: Silencing of pkm2
increases the efficacy of docetaxel in human lung cancer xenografts
in mice. Cancer Sci. 101:1447–1453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cortés-Cros M, Hemmerlin C, Ferretti S,
Zhang J, Gounarides JS, Yin H, Muller A, Haberkorn A, Chene P,
Sellers WR and Hofmann F: M2 isoform of pyruvate kinase is
dispensable for tumor maintenance and growth. Proc Natl Acad Sci
USA. 110:489–494. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen M, Huang SL, Zhang XQ, Zhang B, Zhu
H, Yang VW and Zou XP: Reversal effects of pantoprazole on
multidrug resistance in human gastric adenocarcinoma cells by
down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling
pathway in vitro and in vivo. J Cell Biochem.
113:2474–2487. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spoden GA, Rostek U, Lechner S,
Mitterberger M, Mazurek S and Zwerschke W: Pyruvate kinase
isoenzyme M2 is a glycolytic sensor differentially regulating cell
proliferation, cell size and apoptotic cell death dependent on
glucose supply. Exp Cell Res. 315:2765–2774. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo W, Zhang Y, Chen T, Wang Y, Xue J,
Zhang Y, Xiao W, Mo X and Lu Y: Efficacy of RNAi targeting of
pyruvate kinase M2 combined with cisplatin in a lung cancer model.
J Cancer Res Clin Oncol. 137:65–72. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Spoden GA, Mazurek S, Morandell D, Bacher
N, Ausserlechner MJ, Jansen-Dürr P, Eigenbrodt E and Zwerschke W:
Isotype-specific inhibitors of the glycolytic key regulator
pyruvate kinase subtype M2 moderately decelerate tumor cell
proliferation. Int J Cancer. 123:312–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamanaka RB and Chandel NS: Targeting
glucose metabolism for cancer therapy. J Exp Med. 209:211–215.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tamada M, Suematsu M and Saya H: Pyruvate
kinase M2: Multiple faces for conferring benefits on cancer cells.
Clin Cancer Res. 18:5554–5561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun Q, Chen X, Ma J, Peng H, Wang F, Zha
X, Wang Y, Jing Y, Yang H, Chen R, et al: Mammalian target of
rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is
critical for aerobic glycolysis and tumor growth. Proc Natl Acad
Sci USA. 108:4129–4134. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Won MS, Im N, Park S, Boovanahalli SK, Jin
Y, Jin X, Chung KS, Kang M, Lee K, Park SK, et al: A novel
benzimidazole analogue inhibits the hypoxia-inducible factor
(HIF)-1 pathway. Biochem Biophys Res Commun. 385:16–21. 2009.
View Article : Google Scholar : PubMed/NCBI
|
